All In Biotech

Drug Trial Radar · NCT07036601

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

A Multicenter, Randomized, Double-blind, Placebo-Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of THDBH120 Injection in Overweight or Obese Subjects

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

276

Planned (sponsor's estimate)

Start

Jan 6, 2025

Primary completion

Feb 13, 2026

Study completion Mar 11, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.

Conditions

  • Overweight or Obese

Interventions

  • THDBH120 injectionDrug

    Participants received THDBH120 by subcutaneous injection.

  • Placebo of THDBH120 injectionDrug

    Participants received placebo by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weightTime frame: Baseline, Week26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Xiangya Hospital of Central South University

    Changsha, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.